HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials.

AbstractBACKGROUND:
Acute kidney injury (AKI) is a well-recognized predictor of morbidity and mortality after percutaneous coronary intervention. However, the impact of AKI on the outcome of patients with acute coronary syndromes (ACS) in relation to coronary artery bypass grafting (CABG) has not been established.
METHODS:
Of the 17,421 patients who presented with non-ST-segment elevation ACS or ST-segment elevation myocardial infarction enrolled in the ACUITY and HORIZONS-AMI trials, 1,406 (8.0%) underwent CABG as principal treatment after coronary angiography. End points were measured at 1 month and 1 year and included death, myocardial infarction, and ischemia-driven target vessel revascularization. Acute kidney injury was defined as a rise in creatinine of ≥ 0.5 mg/dL, or > 25%, from baseline at initial angiography.
RESULTS:
Acute kidney injury occurred during hospital admission in 449 (31.9%) of the 1,406 patients treated with CABG. One-month and 1-year mortality was 6.7% vs 2.2% (P < .0001) and 10.4% vs 4.3% (P < .0001) for patients with vs without AKI, respectively. Analogously, the 1-month and 1-year incidence of composite major adverse cardiac events (MACEs; death, MI, or target vessel revascularization) was 17.6% vs 12.4% (P = .003) and 22.0% vs 15.3% (P = .002) for patients with vs without AKI, respectively. After adjustment for age, sex, race, diabetes, hypertension, and baseline creatinine clearance, AKI was an independent predictor of mortality (overall and cardiac-related) and MACE at both 1 month and 1 year in patients treated with CABG.
CONCLUSIONS:
Acute kidney injury occurred in approximately 1 of every 3 patients with ACS treated with CABG and is a powerful independent predictor of death and MACE. These data highlight the need for AKI prevention strategies in patients undergoing CABG.
AuthorsJosephine Warren, Roxana Mehran, Usman Baber, Ke Xu, Daniele Giacoppo, Bernard J Gersh, Giulio Guagliumi, Bernhard Witzenbichler, E Magnus Ohman, Stuart J Pocock, Gregg W Stone
JournalAmerican heart journal (Am Heart J) Vol. 171 Issue 1 Pg. 40-7 (Jan 2016) ISSN: 1097-6744 [Electronic] United States
PMID26699599 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015. Published by Elsevier Inc.
Chemical References
  • Creatinine
Topics
  • Acute Coronary Syndrome (complications, diagnosis, surgery)
  • Acute Kidney Injury (diagnosis, epidemiology, etiology)
  • Aged
  • Cardiac Catheterization
  • Coronary Angiography
  • Coronary Artery Bypass (adverse effects)
  • Creatinine (metabolism)
  • Electrocardiography
  • Europe (epidemiology)
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction (diagnostic imaging, mortality, surgery)
  • Percutaneous Coronary Intervention (methods)
  • Prognosis
  • Prospective Studies
  • Stents
  • Survival Rate (trends)
  • Triage (methods)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: